Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
2,367
Views
26
CrossRef citations to date
0
Altmetric
Brief Report

Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database

Quentin Scanviona Univ. Lille, CHU Lille, Service de Médecine Interne Et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (Ceraino), Lille, FranceORCID Iconhttps://orcid.org/0000-0001-5865-1525
ORCID Icon,
Johana Bénéb Univ. Lille, CHU Lille, Centre Régional de PharmacoVigilance, Lille, France
,
Sophie Gautierb Univ. Lille, CHU Lille, Centre Régional de PharmacoVigilance, Lille, France
,
Aurélie Grandvuilleminc CHU Dijon, Service Vigilances-Qualité-Risques, Centre Régional de PharmacoVigilance, Dijon, France
,
Christine Le Bellerd Hôpital Européen Georges Pompidou, Centre Régional de PharmacoVigilance, Assistance Publique-Hôpitaux de Paris, Paris, France
,
Chouki Chenafe CHU Clermont-Ferrand, Centre Régional de PharmacoVigilance, Clermont-Ferrand, France
,
Nicolas Etiennea Univ. Lille, CHU Lille, Service de Médecine Interne Et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (Ceraino), Lille, France;f Centre de Référence National des Syndromes Hyperéosinophiliques (CEREO), France
,
Solenn Brousseaug Hôpital Bichat, Service d’Oncologie Thoracique, Assistance Publique-Hôpitaux de Paris, Paris, France
,
Alexis B. Cortoth Univ. Lille, UMR8161, CHU Lille, Service d’Oncologie Thoracique, Lille, France
,
Laurent Mortierf Centre de Référence National des Syndromes Hyperéosinophiliques (CEREO), France;i Univ. Lille, Inserm U1189, CHU Lille, Service de Dermatologie, Lille, France
,
Delphine Staumont-Salléf Centre de Référence National des Syndromes Hyperéosinophiliques (CEREO), France;i Univ. Lille, Inserm U1189, CHU Lille, Service de Dermatologie, Lille, France
,
Franck Morschhauserj CHU Lille, Service des Maladies du Sang, Lille, France
,
Alexandra Forestierk Centre Oscar Lambret, Service d’Oncologie, Lille, France
,
Matthieu Grohf Centre de Référence National des Syndromes Hyperéosinophiliques (CEREO), France;l Hôpital Foch, Service de Médecine Interne, Assistance Publique-Hôpitaux de Paris, Suresnes, France
,
David Launaya Univ. Lille, CHU Lille, Service de Médecine Interne Et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (Ceraino), Lille, France
,
Eric Hachullaa Univ. Lille, CHU Lille, Service de Médecine Interne Et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (Ceraino), Lille, France
,
Myriam Labalettef Centre de Référence National des Syndromes Hyperéosinophiliques (CEREO), France;m Univ. Lille, CHU Lille, Institut d’Immunologie, Lille, France
,
Jean-Emmanuel Kahnf Centre de Référence National des Syndromes Hyperéosinophiliques (CEREO), France;n Hôpital Ambroise Paré, Service de Médecine Interne, Assistance Publique-Hôpitaux de Paris, Boulogne Billancourt, France
&
Guillaume Lefèvrea Univ. Lille, CHU Lille, Service de Médecine Interne Et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (Ceraino), Lille, France;f Centre de Référence National des Syndromes Hyperéosinophiliques (CEREO), France;m Univ. Lille, CHU Lille, Institut d’Immunologie, Lille, FranceCorrespondence[email protected]
 show all
Article: 1722022 | Received 15 Jun 2019, Accepted 27 Oct 2019, Published online: 07 Apr 2020

Citations (26)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Hazem Ghebeh, Mahmoud A Elshenawy, Adher D AlSayed & Taher Al-Tweigeri. (2022) Peripheral Blood Eosinophil Count is Associated with Response to Chemoimmunotherapy in Metastatic Triple-Negative Breast Cancer. Immunotherapy 14:4, pages 189-199.
Read now

Articles from other publishers (25)

Karijn P. M. Suijkerbuijk, Mick J. M. van Eijs, Femke van Wijk & Alexander M. M. Eggermont. (2024) Clinical and translational attributes of immune-related adverse events. Nature Cancer.
Crossref
Ryo Mitsui, Shun Kasahara, Shuji Uchida, Takuya Shimooka, Kohei Kawamura, Takayuki Hara, Shin-ichiro Hiraoka, Hisao Sano, Susumu Tanaka & Taroh Satoh. (2024) A case of eosinophilic gastroenteritis developed during administration of nivolumab for a patient with platinum-resistant head and neck cancer. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology.
Crossref
Clément Cholle, Johanna Rousset, Paola Sanchez-Pena, Audrey Fresse, Nathalie Vernier, Hervé Devilliers & Aurélie Grandvuillemin. (2023) Asymptomatic drug-induced peripheral blood eosinophilia: A retrospective study using the French national pharmacovigilance database. Therapies 78:6, pages 766-768.
Crossref
Yushi Ueki, Shusuke Ohshima, Jo Omata, Yusuke Yokoyama, Takeshi Takahashi, Ryusuke Shodo, Keisuke Yamazaki & Arata Horii. (2023) Role of eosinophilia in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab: Prediction of immune‐related adverse events and favorable outcome. Cancer Medicine 12:22, pages 20810-20820.
Crossref
Yala Kirthi Reddy, Inderbitzin Sonya Fischer, Joanna Kolodney & Megan Willard. (2023) A Curious Case of Gastrointestinal Eosinophilia Induced by Treatment With Immune Checkpoint Inhibitors. ACG Case Reports Journal 10:6, pages e01075.
Crossref
Gunhild Nynke Thomsen, Mette Niemann Christoffersen, Hanne Merete Lindegaard, Jesper Rømhild Davidsen, Gitte Nyvang Hartmeyer, Kristian Assing, Charlotte G. Mortz, Raquel Martin-Iguacel, Michael Boe Møller, Anette Drøhse Kjeldsen, Troels Havelund, Daniel El Fassi, Sigurd Broesby-Olsen, Michael Maiborg, Sofie Lock Johansson, Christen Lykkegaard Andersen, Hanne Vestergaard & Ole Weis Bjerrum. (2023) The multidisciplinary approach to eosinophilia. Frontiers in Oncology 13.
Crossref
Ignacio Melero, Tamara Tanos, Mariana Bustamante, Miguel F. SanmamedEmiliano Calvo, Irene Moreno, Victor Moreno, Tatiana Hernandez, Maria Martinez Garcia, Alejo Rodriguez-Vida, Josep Tabernero, Analia Azaro, Mariano Ponz-Sarvisé, Iben Spanggaard, Kristoffer Rohrberg, Ernesto GuarinEveline NüeschIakov I. Davydov, Chiahuey Ooi, José Duarte, Evelyne Chesne, Christine McIntyreMaurizio Ceppi, Marta Cañamero & Oliver Krieter. (2023) A first-in-human study of the fibroblast activation protein–targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors. Science Translational Medicine 15:695.
Crossref
Matthieu Groh, Julien Rohmer, Nicolas Etienne, Wadih Abou Chahla, Antoine Baudet, Aurélie Chan Hew Wai, Cécile Chenivesse, Irena Clisson Rusek, Vincent Cottin, Matthieu Decamp, Pascal De Groote, Fanny Delahousse, Nicolas Duployez, Stanislas Faguer, Frédéric Gottrand, Florent Huang, Thierry Leblanc, Antoine Magnan, Thierry Martin, Geoffrey Mortuaire, Antoine Néel, Luc Paris, Arnaud Petit, Julien Rossignol, Nicolas Schleinitz, Juliette Soret-Dulphy, Delphine Staumont-Salle, Benjamin Terrier, Louis Terriou, Jean-François Viallard, Guillaume Lefèvre & Jean-Emmanuel Kahn. (2023) French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes. Orphanet Journal of Rare Diseases 18:1.
Crossref
Almog Shalit, Panagiotis Sarantis, Evangelos Koustas, Eleni-Myrto Trifylli, Dimitris Matthaios & Michalis V. Karamouzis. (2023) Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment. Cancers 15:2, pages 375.
Crossref
Mick J. M. van Eijs, Lotte E. van der Wagen, Rogier Mous, Roos J. Leguit, Lisette van de Corput, Anne S. R. van Lindert, Britt B. M. Suelmann, Anna M. Kamphuis, Stefan Nierkens & Karijn P. M. Suijkerbuijk. (2022) Hematologic malignancies following immune checkpoint inhibition for solid tumors. Cancer Immunology, Immunotherapy 72:1, pages 249-255.
Crossref
Gaik Tin Quah, Gillian Blanchard, Neil Miller, Paul Wilson & Ina Nordman. (2022) Strongyloides —An uncommon cause of eosinophilia whilst on durvalumab . Cancer Reports 5:10.
Crossref
Simone Wendlinger, Jonas Wohlfarth, Sophia Kreft, Claudia Siedel, Teresa Kilian, Ulrich Dischinger, Markus V. Heppt, Kilian Wistuba-Hamprecht, Friedegund Meier, Matthias Goebeler, Dirk Schadendorf, Anja Gesierich, Corinna Kosnopfel & Bastian Schilling. (2022) Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma. Cancers 14:9, pages 2294.
Crossref
Anne Sibille, Jean-Louis Corhay, Renaud Louis, Vincent Ninane, Guy Jerusalem & Bernard Duysinx. (2022) Eosinophils and Lung Cancer: From Bench to Bedside. International Journal of Molecular Sciences 23:9, pages 5066.
Crossref
Shinobu Takayasu, Satoru Mizushiri, Yutaka Watanuki, Satoshi Yamagata, Mari Usutani, Yuki Nakada, Yuko Asari, Shingo Murasawa, Kazunori Kageyama & Makoto Daimon. (2022) Eosinophil counts can be a predictive marker of immune checkpoint inhibitor-induced secondary adrenal insufficiency: a retrospective cohort study. Scientific Reports 12:1.
Crossref
Ella C. Berry, Sean Mullany, Alannah Quinlivan, Amelia Craig, Julia New-Tolley, James Slattery, Shawgi Sukumaran, Sonja Klebe, Jamie E. Craig, Owen M. Siggs & Mihir D. Wechalekar. (2022) Eosinophilic Vasculitis and Arteritic Anterior Ischemic Optic Neuropathy Associated With Anti-PD-L1 Therapy. Journal of Immunotherapy 45:1, pages 51-55.
Crossref
Masanori Harada, Hyogo Naoi, Kazuyo Yasuda, Yutaro Ito, Namio Kagoo, Tsutomu Kubota, Koshiro Ichijo, Eisuke Mochizuki, Masahiro Uehara, Shun Matsuura, Masaru Tsukui & Naoki Koshimizu. (2021) Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: a case report. BMC Pulmonary Medicine 21:1.
Crossref
Kim Dao, Thierry Kuntzer, Philippe Maeder, Valerie Frossard & Francoise Livio. (2021) Pembrolizumab-induced massive hypereosinophilia associated with mononeuritis multiplex, brain microvascular lesions and intestinal eosinophilic infiltration in a melanoma patient. Current Problems in Cancer: Case Reports 4, pages 100133.
Crossref
Alexandre O. Gérard, Marine Andreani, Audrey Fresse, Nadège Parassol, Marine Muzzone, Sylvine Pinel, Delphine Bourneau-Martin, Delphine Borchiellini, Fanny Rocher, Vincent L. M. Esnault & Milou-Daniel Drici. (2021) Immune checkpoint inhibitors-induced nephropathy: a French national survey. Cancer Immunology, Immunotherapy 70:11, pages 3357-3364.
Crossref
Toshiyuki Sumi, Yuta Nagahisa, Keigo Matsuura, Motoki Sekikawa, Yuichi Yamada, Hisashi Nakata & Hirofumi Chiba. (2021) Successful management of severe bronchial asthma exacerbated by anti‐PD‐L1 treatment: A report of two cases . Respirology Case Reports 9:11.
Crossref
Kazuko Sakai, Toshiharu Sakurai, Marco A. De Velasco, Tomoyuki Nagai, Takaaki Chikugo, Kazuomi Ueshima, Yurie Kura, Takayuki Takahama, Hidetoshi Hayashi, Kazuhiko Nakagawa, Masatoshi Kudo & Kazuto Nishio. (2021) Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis. Frontiers in Oncology 11.
Crossref
David J. Lee, Howard J. LeeJrJr, Jocelyn R. Farmer & Kerry L. Reynolds. (2021) Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors. Current Cardiology Reports 23:8.
Crossref
Angel R Baroz, Isa Mambetsariev, Jeremy Fricke, Rebecca Pharaon, TingTing Tan, Trilokesh Kidambi, Karamjeet S Sandhu, Marianna Koczywas & Ravi Salgia. (2021) Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer. Cureus.
Crossref
Julie Belliere, Julien Mazieres, Nicolas Meyer, Leila Chebane & Fabien Despas. (2021) Renal Complications Related to Checkpoint Inhibitors: Diagnostic and Therapeutic Strategies. Diagnostics 11:7, pages 1187.
Crossref
Bożena Cybulska-Stopa, Grażyna Kamińska-Winciorek & Grzegorz Dyduch. (2020) Immune-related adverse events in a patient with eosinophilic enteritis treated with immune checkpoint inhibitors (anti-PD-1). Melanoma Research 30:6, pages 619-624.
Crossref
. (2020) Ipilimumab/nivolumab/pembrolizumab. Reactions Weekly 1804:1, pages 162-162.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.